Osteoporosis

First patients given AMG 162 in phase III studies for bone loss

Published in Drug Week, September 10th, 2004

Amgen, Inc., (AMGN) announced that the first patients have been dosed in two pivotal phase III trials of AMG 162, the company's fully human monoclonal antibody being investigated for potential use in postmenopausal osteoporosis and treatment-induced bone loss.

AMG 162 is an investigational, fully human monoclonal antibody that specifically binds to and inhibits RANK Ligand, the primary mediator of bone resorption. Amgen scientists have confirmed that RANK Ligand is the protein responsible for activating osteoclasts, the cells that break down bone.

Excessive RANK Ligand has been identified as the primary cause of a broad range of bone loss conditions...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-09-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry